Cardiovascular toxicity due to DOX administration, which has become a risk in cancer treatment, can be attributed to anti-VEGF agents where suppression of VEGF expression, through changes in NO inhibition and endothelin stimulation (ET1), determines endothelial dysfunction and vasoconstriction, which are major factors in hypertension [102]. This evidence concerns the gene EDN1 and endothelial dysfunction.